Low testosterone in men with type 2 diabetes: Significance and treatment

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 8, 2011, Pages 2341-2353

  Grossmann, Mathis ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE; TESTOSTERONE ESTER; TESTOSTERONE UNDECANOATE;

ANDROGEN DEFICIENCY; ANDROGEN THERAPY; BODY COMPOSITION; BONE; CHRONIC DISEASE; COMPARATIVE STUDY; DIET THERAPY; DISEASE ASSOCIATION; DISEASE MARKER; EXERCISE; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; INTRAABDOMINAL FAT; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MUSCLE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW (TOPIC); TESTOSTERONE BLOOD LEVEL; TREATMENT RESPONSE;

ANDROGENS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGONADISM; MALE; TESTOSTERONE;

EID: 79961243360     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-0118     Document Type: Review

References (115)

1. Cowie CC, Rust KF, Byrd-Holt DD, Gregg EW, Ford ES, Geiss LS, Bainbridge KE, Fradkin JE 2010 Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006. Diabetes Care 33:562-568
2. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR 2001 Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 86:724-731 (Pubitemid 32207487)
3. Shaw JE, Sicree RA, Zimmet PZ 2010 Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87:4-14
4. Orwoll ES, Nielson CM, Labrie F, Barrett-Connor E, Cauley JA, Cummings SR, Ensrud K, Karlsson M, Lau E, Leung PC, Lunggren O, Mellström D, Patrick AL, Stefanick ML, Nakamura K, Yoshimura N, Zmuda J, Vandenput L, Ohlsson C 2010 Evidence for geographical and racial variation in serum sex steroid levels in older men. J Clin Endocrinol Metab 95:E151-E160
5. Ding EL, Song Y, Malik VS, Liu S 2006 Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 295:1288-1299
6. Corona G, Monami M, Rastrelli G, Aversa A, Sforza A, Lenzi A, Forti G, Mannucci E, Maggi M 24 October 2010 Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl doi: 10.1111/j.1365-2605.2010.01117.x
7. Selvin E, Feinleib M, Zhang L, Rohrmann S, Rifai N, Nelson WG, Dobs A, Basaria S, Golden SH, Platz EA 2007 Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 30:234-238 (Pubitemid 46198324)
8. Brand JS, Wareham NJ, Dowsett M, Folkerd E, van der Schouw YT, Luben RN, Khaw KT 15 December 2010 Associations of endogenous testosterone and SHBG with glycated haemoglobin in middle-aged and older men. Clin Endocrinol (Oxf) doi: 10.1111/j.1365-2265.2010.03951.x
9. Grossmann M, Thomas MC, Panagiotopoulos S, Sharpe K, Macisaac RJ, Clarke S, Zajac JD, Jerums G 2008 Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab 93:1834-1840 (Pubitemid 351656526)
10. Kapoor D, Aldred H, Clark S, Channer KS, Jones TH 2007 Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 30:911-917 (Pubitemid 46556586)
11. Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P 2004 Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 89:5462-5468 (Pubitemid 39518427)
12. Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O'Neill TW, Bartfai G, Casanueva F, Forti G, Giwercman A, Huhtaniemi IT, Kula K, Punab M, Boonen S, Vanderschueren D 2008 Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 93:2737-2745 (Pubitemid 352008544)
13. Tajar A, Forti G, O'Neill TW, Lee DM, Silman AJ, Finn JD, Bartfai G, Boonen S, Casanueva FF, Giwercman A, Han TS, Kula K, Labrie F, Lean ME, Pendleton N, Punab M, Vanderschueren D, Huhtaniemi IT, Wu FC 2010 Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab 95:1810-1818
14. Allan CA, McLachlan RI 2010 Androgens and obesity. Curr Opin Endocrinol Diabetes Obes 17:224-232
15. Dhindsa S, Miller MG, McWhirter CL, Mager DE, Ghanim H, Chaudhuri A, Dandona P 2010 Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care 33:1186-1192
16. Haffner SM, Shaten J, Stern MP, Smith GD, Kuller L 1996 Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Am J Epidemiol 143:889-897 (Pubitemid 26131096)
17. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB 2000 Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts Male Aging Study. Diabetes Care 23:490-494 (Pubitemid 30185792)
18. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL 2002 Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo Study. Diabetes Care 25:55-60 (Pubitemid 41070783)
19. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT 2004 Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27:1036-1041 (Pubitemid 38579762)
20. Vikan T, Schirmer H, Njølstad I, Svartberg J 2010 Low testosterone and sex hormone-binding globulin levels and high estradiol levels are independent predictors of type 2 diabetes in men. Eur J Endocrinol 162:747-754
21. Lakshman KM, Bhasin S, Araujo AB 2010 Sex hormone-binding globulin as an independent predictor of incident type 2 diabetes mellitus in men. J Gerontol A Biol Sci Med Sci 65:503-509
22. Li C, Ford ES, Li B, Giles WH, Liu S 2010 Association of testosterone and sex hormone-binding globulin with metabolic syndrome and insulin resistance in men. Diabetes Care 33:1618-1624
23. Brand JS, van der Tweel I, Grobbee DE, Emmelot-Vonk MH, van der Schouw YT 2011 Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol 40:189-207
24. Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, Lenzi A, Forti G, Mannucci E, Maggi M 2011 Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 8:272-283
25. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB 2006 Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 91:843-850 (Pubitemid 43357748)
26. Kalyani RR, Gavini S, Dobs AS 2007 Male hypogonadism in systemic disease. Endocrinol Metab Clin North Am 36:333-348 (Pubitemid 46817893)
27. Rosner W, Vesper H 2010 Toward excellence in testosterone testing: a consensus statement. J Clin Endocrinol Metab 95:4542-4548
28. Ly LP, Sartorius G, Hull L, Leung A, Swerdloff RS, Wang C, Handelsman DJ 2010 Accuracy of calculated free testosterone formulae in men. Clin Endocrinol (Oxf) 73:382-388
29. Ding EL, Song Y, Manson JE, Hunter DJ, Lee CC, Rifai N, Buring JE, Gaziano JM, Liu S 2009 Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med 361:1152-1163
30. Perry JR, Weedon MN, Langenberg C, Jackson AU, Lyssenko V, Sparsø T, Thorleifsson G, Grallert H, Ferrucci L, Maggio M, Paolisso G, Walker M, Palmer CN, Payne F, Young E, Herder C, Narisu N, Morken MA, Bonnycastle LL, Owen KR, Shields B, Knight B, Bennett A, Groves CJ, Ruokonen A, Jarvelin MR, Pearson E, Pascoe L, Ferrannini E, Bornstein SR, Stringham HM, Scott LJ, Kuusisto J, Nilsson P, Neptin M, Gjesing AP, Pisinger C, Lauritzen T, Sandbaek A, Sampson M, Zeggini E, Lindgren CM, Steinthorsdottir V, Thorsteinsdottir U, Hansen T, Schwarz P, Illig T, Laakso M, Stefansson K, Morris AD, Groop L, Pedersen O, Boehnke M, Barroso I, Wareham NJ, Hattersley AT, McCarthy MI, Frayling TM 2010 Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes. Hum Mol Genet 19:535-544
31. Yeap BB, Chubb SA, Hyde Z, Jamrozik K, Hankey GJ, Flicker L, Norman PE 2009 Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men: the Health in Men Study. Eur J Endocrinol 161:591-598
32. Pitteloud N, Mootha VK, Dwyer AA, Hardin M, Lee H, Eriksson KF, Tripathy D, Yialamas M, Groop L, Elahi D, Hayes FJ 2005 Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 28:1636-1642 (Pubitemid 41340902)
33. Abate N, Haffner SM, Garg A, Peshock RM, Grundy SM 2002 Sex steroid hormones, upper body obesity, and insulin resistance. J Clin Endocrinol Metab 87:4522-4527 (Pubitemid 35247035)
34. Tchernof A, Després JP, Dupont A, Bélanger A, Nadeau A, Prud'homme D, Moorjani S, Lupien PJ, Labrie F 1995 Relation of steroid hormones to glucose tolerance and plasma insulin levels in men. Importance of visceral adipose tissue. Diabetes Care 18:292-299
35. Tsai EC, Matsumoto AM, Fujimoto WY, Boyko EJ 2004 Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat. Diabetes Care 27:861-868 (Pubitemid 38420205)
36. Bojesen A, Kristensen K, Birkebaek NH, Fedder J, Mosekilde L, Bennett P, Laurberg P, Frystyk J, Flyvbjerg A, Christiansen JS, Gravholt CH 2006 The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care 29:1591-1598 (Pubitemid 44127586)
37. Kupelian V, Hayes FJ, Link CL, Rosen R, McKinlay JB 2008 Inverse association of testosterone and the metabolic syndrome in men is consistent across race and ethnic groups. J Clin Endocrinol Metab 93:3403-3410
38. Corona G, Mannucci E, Petrone L, Balercia G, Paggi F, Fisher AD, Lotti F, Chiarini V, Fedele D, Forti G, Maggi M 2007 NCEP-ATPIII-defined metabolic syndrome, type 2 diabetes mellitus, and prevalence of hypogonadism in male patients with sexual dysfunction. J Sex Med 4:1038-1045 (Pubitemid 47079637)
39. Hall SA, Esche GR, Araujo AB, Travison TG, Clark RV, Williams RE, McKinlay JB 2008 Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample. J Clin Endocrinol Metab 93:3870-3877
40. Couillard C, Gagnon J, Bergeron J, Leon AS, Rao DC, Skinner JS, Wilmore JH, Després JP, Bouchard C 2000 Contribution of body fatness and adipose tissue distribution to the age variation in plasma steroid hormone concentrations in men: the HERITAGE Family Study. J Clin Endocrinol Metab 85:1026-1031 (Pubitemid 32269344)
41. Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S 2003 Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 144:5081-5088 (Pubitemid 37378423)
42. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A 2005 Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 63:280-293 (Pubitemid 41233445)
43. Bhasin S, Calof OM, Storer TW, Lee ML, Mazer NA, Jasuja R, Montori VM, Gao W, Dalton JT 2006 Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab 2:146-159
44. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW 2002 Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87:599-603 (Pubitemid 34158224)
45. Hamilton EJ, Gianatti E, Strauss BJ, Wentworth J, Lim-Joon D, Bolton D, Zajac JD, Grossmann M 2011 Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol (Oxf) 74:377-383
46. Keating NL, O'Malley AJ, Smith MR 2006 Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24:4448-4456 (Pubitemid 46630983)
47. Grossmann M, Zajac JD 2011 Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated? Clin Endocrinol (Oxf) 74:289-293
48. Sato T, Matsumoto T, Yamada T, Watanabe T, Kawano H, Kato S 2003 Late onset of obesity in male androgen receptor-deficient (AR KO) mice. Biochem Biophys Res Commun 300:167-171 (Pubitemid 36042946)
49. Fan W, Yanase T, Nomura M, Okabe T, Goto K, Sato T, Kawano H, Kato S, Nawata H 2005 Androgen receptor null male mice develop late-onset obesity caused by decreased energy expenditure and lipolytic activity but show normal insulin sensitivity with high adiponectin secretion. Diabetes 54:1000-1008 (Pubitemid 40450323)
50. Notini AJ, Davey RA, McManus JF, Bate KL, Zajac JD 2005 Genomic actions of the androgen receptor are required for normal male sexual differentiation in a mouse model. J Mol Endocrinol 35:547-555 (Pubitemid 43025578)
51. Xu XF, De Pergola G, Björntorp P 1991 Testosterone increases lipolysis and the number of β-adrenoceptors in male rat adipocytes. Endocrinology 128:379-382
52. Mårin P, Odén B, Björntorp P 1995 Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab 80:239-243
53. Holmäng A, Björntorp P 1992 The effects of testosterone on insulin sensitivity in male rats. Acta Physiol Scand 146:505-510 (Pubitemid 23008349)
54. Haren MT, Siddiqui AM, Armbrecht HJ, Kevorkian RT, Kim MJ, Haas MJ, Mazza A, Kumar VB, Green M, Banks WA, Morley JE 2011 Testosterone modulates gene expression pathways regulating nutrient accumulation, glucose metabolism and protein turnover in mouse skeletal muscle. Int J Androl 34:55-68
55. Fernando SM, Rao P, Niel L, Chatterjee D, Stagljar M, Monks DA 2010 Myocyte androgen receptors increase metabolic rate and improve body composition by reducing fat mass. Endocrinology 151:3125-3132
56. Yu IC, Lin HY, Liu NC, Wang RS, Sparks JD, Yeh S, Chang C 2008 Hyperleptinemia without obesity in male mice lacking androgen receptor in adipose tissue. Endocrinology 149:2361-2368 (Pubitemid 351574489)
57. Lin HY, Yu IC, Wang RS, Chen YT, Liu NC, Altuwaijri S, Hsu CL, Ma WL, Jokinen J, Sparks JD, Yeh S, Chang C 2008 Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. Hepatology 47:1924-1935 (Pubitemid 351945560)
58. Völzke H, Aumann N, Krebs A, Nauck M, Steveling A, Lerch MM, Rosskopf D, Wallaschofski H 2010 Hepatic steatosis is associated with low serum testosterone and high serum DHEAS levels in men. Int J Androl 33:45-53
59. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G 2007 Endocrine regulation of energy metabolism by the skeleton. Cell 130:456-469 (Pubitemid 47208519)
60. Oury F, Sumara G, Sumara O, Ferron M, Chang H, Smith CE, Hermo L, Suarez S, Roth BL, Ducy P, Karsenty G 2011 Endocrine regulation of male fertility by the skeleton. Cell 144:796-809
61. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Kurioka S, Yano S, Sugimoto T 2009 Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab 94:45-49
62. Yeap BB, Chubb SA, Flicker L, McCaul KA, Ebeling PR, Beilby JP, Norman PE 2010 Reduced serum total osteocalcin is associated with metabolic syndrome in older men via waist circumference, hyperglycemia, and triglyceride levels. Eur J Endocrinol 163:265-272
63. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, Valkonen VP, Salonen JT 2005 The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab 90:712-719 (Pubitemid 40279184)
64. Tsai EC, Boyko EJ, Leonetti DL, Fujimoto WY 2000 Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men. Int J Obes Relat Metab Disord 24:485-491 (Pubitemid 30198102)
65. Travison TG, Araujo AB, Kupelian V, O'Donnell AB, McKinlay JB 2007 The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab 92:549-555
66. Haring R, Ittermann T, Völzke H, Krebs A, Zygmunt M, Felix SB, Grabe HJ, Nauck M, Wallaschofski H 2010 Prevalence, incidence and risk factors of testosterone deficiency in a population-based cohort of men: results from the study of health in Pomerania. Aging Male 13:247-257
67. Grossmann M, Gianatti EJ, Zajac JD 2010 Testosterone and type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 17:247-256
68. Traish AM, Saad F, Guay A 2009 The dark side of testosterone deficiency. II. Type 2 diabetes and insulin resistance. J Androl 30:23-32
69. Stanworth RD, Jones TH 2009 Testosterone in obesity, metabolic syndrome and type 2 diabetes. Front Horm Res 37:74-90
70. Zitzmann M 2009 Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol 5:673-681
71. Vermeulen A, Kaufman JM, Deslypere JP, Thomas G 1993 Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. J Clin Endocrinol Metab 76:1140-1146 (Pubitemid 23155426)
72. Zumoff B, Miller LK, Strain GW 2003 Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone. Metabolism 52:1126-1128 (Pubitemid 37203485)
73. Pitteloud N, Hardin M, Dwyer AA, Valassi E, Yialamas M, Elahi D, Hayes FJ 2005 Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 90:2636-2641 (Pubitemid 40686302)
74. Liu PY, Death AK, Handelsman DJ 2003 Androgens and cardiovascular disease. Endocr Rev 24:313-340 (Pubitemid 36724373)
75. Idan A, Griffiths KA, Harwood DT, Seibel MJ, Turner L, Conway AJ, Handelsman DJ 2010 Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial. Ann Intern Med 153:621-632
76. Zitzmann M, Gromoll J, Nieschlag E 2005 The androgen receptor CAG repeat polymorphism. Andrologia 37:216
77. Bhasin S, Storer TW 2009 Anabolic applications of androgens for functional limitations associated with aging and chronic illness. Front Horm Res 37:163-182
78. Blouin K, Boivin A, Tchernof A 2008 Androgens and body fat distribution. J Steroid Biochem Mol Biol 108:272-280 (Pubitemid 351179628)
79. Colangelo LA, Ouyang P, Liu K, Kopp P, Golden SH, Dobs AS, Szklo M, Vaidya D, Cushman M, Gapstur SM 2009 Association of endogenous sex hormones with diabetes and impaired fasting glucose in men: multi-ethnic study of atherosclerosis. Diabetes Care 32:1049-1051
80. Stanik S, Dornfeld LP, Maxwell MH, Viosca SP, Korenman SG 1981 The effect of weight loss on reproductive hormones in obese men. J Clin Endocrinol Metab 53:828-832 (Pubitemid 13238668)
81. Pritchard J, Després JP, Gagnon J, Tchernof A, Nadeau A, Tremblay A, Bouchard C 1999 Plasma adrenal, gonadal, and conjugated steroids following long-term exercise-induced negative energy balance in identical twins. Metabolism 48:1120-1127 (Pubitemid 29418281)
82. Kaukua J, Pekkarinen T, Sane T, Mustajoki P 2003 Sex hormones and sexual function in obese men losing weight. Obes Res 11:689-694 (Pubitemid 41151594)
83. Niskanen L, Laaksonen DE, Punnonen K, Mustajoki P, Kaukua J, Rissanen A 2004 Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab 6:208-215 (Pubitemid 38559701)
84. Khoo J, Piantadosi C, Worthley S, Wittert GA 2010 Effects of a low-energy diet on sexual function and lower urinary tract symptoms in obese men. Int J Obes (Lond) 34:1396-1403
85. Globerman H, Shen-Orr Z, Karnieli E, Aloni Y, Charuzi I 2005 Inhibin B in men with severe obesity and after weight reduction following gastroplasty. Endocr Res 31:17-26 (Pubitemid 41419981)
86. Hammoud A, Gibson M, Hunt SC, Adams TD, Carrell DT, Kolotkin RL, Meikle AW 2009 Effect of Roux-en-Y gastric bypass surgery on the sex steroids and quality of life in obese men. J Clin Endocrinol Metab 94:1329-1332
87. Omana JJ, Tamler R, Strohmayer E, Herron D, Kini S 2009 Sex hormone levels in men undergoing bariatric surgery. J Am Coll Surg 209(3 Suppl):S22-S23
88. Kraemer WJ, Ratamess NA 2005 Hormonal responses and adaptations to resistance exercise and training. Sports Med 35:339-361 (Pubitemid 40593621)
89. Saad F, Gooren LJ 2011 The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2. J Obes pii:471584
90. Allan CA, Strauss BJ, Forbes EA, McLachlan RI, Testosterone therapy improves body composition and metabolic parameters in obese aging men: results of a placebo-controlled randomized controlled trial. Program of the 92nd Annual Meeting of The Endocrine Society, San Diego, 2010 (P2-455)
91. Singh AB, Hsia S, Alaupovic P, Sinha-Hikim I, Woodhouse L, Buchanan TA, Shen R, Bross R, Berman N, Bhasin S 2002 The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab 87:136-143 (Pubitemid 34084682)
92. Kapoor D, Goodwin E, Channer KS, Jones TH 2006 Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 154:899-906 (Pubitemid 43997730)
93. Gopal RA, Bothra N, Acharya SV, Ganesh HK, Bandgar TR, Menon PS, Shah NS 2010 Treatment of hypogonadism with testosterone in patients with type 2 diabetes mellitus. Endocr Pract 16:570-576
94. Heufelder AE, Saad F, Bunck MC, Gooren L 2009 Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 30:726-733
95. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F 2010 Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) 73:602-612
96. Aversa A, Bruzziches R, Francomano D, Rosano G, Isidori AM, Lenzi A, Spera G 2010 Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 7:3495-3503
97. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, Morales AM, Volterrani M, Yellowlees A, Howell JD, Channer KS 2011 Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 Study). Diabetes Care 34:828-837
98. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL 2005 Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 90:1502-1510 (Pubitemid 40464011)
99. Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, D'Armiento M, D'Andrea F, Giugliano D 2004 Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 292:1440-1446 (Pubitemid 39258336)
100. Church TS, Blair SN, Cocreham S, Johannsen N, Johnson W, Kramer K, Mikus CR, Myers V, Nauta M, Rodarte RQ, Sparks L, Thompson A, Earnest CP 2010 Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: a randomized controlled trial. JAMA 304:2253-2262
101. Belalcazar LM, Reboussin DM, Haffner SM, Hoogeveen RC, Kriska AM, Schwenke DC, Tracy RP, Pi-Sunyer FX, Ballantyne CM 2010 A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care 33:2297-2303
102. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D 2005 Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 3:CD002966
103. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF 2002 The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51:797-802 (Pubitemid 34760191)
104. Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Boloña ER, Sideras K, Uraga MV, Erwin PJ, Montori VM 2007 Testosterone and cardiovascular risk in men: a systematic review and metaanalysis of randomized placebo-controlled trials. Mayo Clin Proc 82:29-39 (Pubitemid 46036319)
105. Fernández-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT, Erwin PJ, Bhasin S, Montori VM 2010 Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 95:2560-2575
106. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S 2005 Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 60:1451-1457 (Pubitemid 41798454)
107. O'Connell MD, Roberts SA, Srinivas-Shankar U, Tajar A, Connolly MJ, Adams JE, Oldham JA, Wu FC 2011 Do the effects of testosterone on muscle strength, physical function, body composition, and quality of life persist six months after treatment in intermediate-frail and frail elderly men? J Clin Endocrinol Metab 96:454-458
108. Yudkin JS, Richter B, Gale EA 2010 Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia 53:2079-2085
109. Yeap BB 2010 Androgens and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 17:269-276
110. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S 2010 Adverse events associated with testosterone administration. N Engl J Med 363:109-122
111. Srinivas-Shankar U, Roberts SA, Connolly MJ, O'Connell MD, Adams JE, Oldham JA, Wu FC 2010 Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 95:639-650
112. Grossmann M, Panagiotopolous S, Sharpe K, MacIsaac RJ, Clarke S, Zajac JD, Jerums G, Thomas MC 2009 Low testosterone and anaemia in men with type 2 diabetes. Clin Endocrinol (Oxf) 70:547-553
113. Atlantis E, Lange K, Martin S, Haren MT, Taylor A, O'Loughlin PD, Marshall V, Wittert GA 2011 Testosterone and modifiable risk factors associated with diabetes in men. Maturitas 68:279-285
114. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM 2010 Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 95:2536-2559
115. Cunningham GR, Toma SM 2011 Clinical review: why is androgen replacement in males controversial? J Clin Endocrinol Metab 96:38-52